Levofloxacin prophylaxis in hospitalized children with leukemia: A cost‐utility analysis. Issue 10 (12th August 2020)

• Record Type: Journal Article
• Authors: Maser, Brandon; Pelland‐Marcotte, Marie‐Claude; Alexander, Sarah; Sung, Lillian; Gupta, Sumit
• Is Part Of: Pediatric blood & cancer. Volume 67:Issue 10(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-08-12
• Subjects: antibiotic prophylaxis -- bacteremia -- infections -- leukemia; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.28643
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Background: Infections are common and are a major cause of morbidity and mortality during treatment of childhood leukemia. We evaluated the cost effectiveness of levofloxacin antibiotic prophylaxis, compared to no prophylaxis, in children receiving chemotherapy for acute myeloid leukemia (AML) or relapsed acute lymphoblastic leukemia (ALL). Procedures: A cost‐utility analysis was conducted from the perspective of the single‐payer health care system using a lifetime horizon. A comprehensive literature review identified available evidence for effectiveness, safety, costs of antibiotic prophylaxis in children with leukemia, and health utilities associated with the relevant health states. The effects of levofloxacin prophylaxis on health outcomes, quality‐adjusted life‐years (QALY), and direct health costs were derived from a combined decision tree and state‐transition model. One‐way deterministic and probabilistic sensitivity analyses were performed to test the sensitivity of results to parameter uncertainty. Results: The literature review revealed one randomized controlled trial on levofloxacin prophylaxis in childhood AML and relapsed ALL, by Alexander et al, that showed a significant reduction in rates of fever and neutropenia (71.2% vs 82.1%) and bacteremia (21.9% vs 43.4%) with levofloxacin compared to no prophylaxis. In our cost‐utility analysis, levofloxacin prophylaxis was dominant over no prophylaxis, resulting in cost savings of $542.44 and increased survival of 0.13 QALY. In probabilistic sensitivity analysis, levofloxacin prophylaxis was dominant in 98.8% of iterations. Conclusions: The present analysis suggests that levofloxacin prophylaxis, compared to no prophylaxis, is cost saving in children receiving intensive chemotherapy for AML or relapsed ALL.